Report: Class-action Securities Lawsuits Decline but Risks Remain for Life-sciences Companies
Disgruntled investors lodged fewer securities claims against life-science companies last year. But when they did sue, investors raised familiar issues, often tied to bad news around clinical research and regulatory approvals, according to a law firm report
